title: Comparison of full-length genomics sequences between dengue virus serotype 3, parental strain, and its derivatives, and B-cell epitopes prediction from envelope region.
abstract: Biological markers are normally used to evaluate the candidate of live-attenuated dengue vaccines. D3V 16562 Vero 23 and D3V 16562 Vero 33 which were derivatives of D3V 16562, parental strain, showed the similar biological data. We used molecular techniques and computational tools to evaluate these derivatives. The nucleotide and amino acid sequences of the derivatives were compared to their parent. The secondary structures of untranslated regions and B-cell epitopes were predicted. The results showed that nucleotide substitutions mostly occurred in NS5 and NS5 of V2 was unusual because of amino acid change at 3349 (tryptophan →stop codon). The nucleotide substitutions in 5'UTR, prM, E, NS1, NS2A, NS3, and 3'UTR were 4, 1, 2, 2, 1, 3, and 2, respectively. The secondary structure of 5'UTR of V2 was different from P and V1. The secondary structure of 3'UTR of V2 was similar to P and certainly distinct from V1. Furthermore, B-cell epitopes prediction revealed that there were 21 epitopes of envelope and the interesting epitope was at position 297-309 because it was in domain III in which the neutralizing antibody is induced. For this study, the attenuation of derivatives was caused by the nucleotide substitutions in 5'UTR, 3'UTR, and NS5 regions. The genotypic data and B-cell epitope make the derivatives attractive for the chimeric and peptide DENV vaccine development.
authors.affiliation: Department of Biology, Faculty of Science, Silpakorn University, Nakhon Pathom, Thailand.
authors.forename: Siriwattana
authors.initials: S
authors.lastname: Thaisonthi
authors.forename: Jundee
authors.initials: J
authors.lastname: Rabablert
authors.forename: Sutee
authors.initials: S
authors.lastname: Yoksan
keywords: 5'-3'UTR secondary structure; Dengue virus; Live-attenuated dengue vaccine; dengue epitope
references.citation: Cell. 2002 Mar 8;108(5):717-25
references.pmid: 11893341
references.citation: Annu Rev Immunol. 2011;29:587-619
references.pmid: 21219187
references.citation: Vaccine. 2011 Jan 17;29(4):831-8
references.pmid: 21115054
references.citation: J Virol Methods. 2010 Oct;169(1):202-6
references.pmid: 20600330
references.citation: J Virol. 2007 Sep;81(17):9591-5
references.pmid: 17553878
references.citation: Arch Virol. 2008;153(10):1967-70
references.pmid: 18815724
references.citation: J Virol. 2001 Aug;75(16):7769-73
references.pmid: 11462053
references.citation: J Biomed Biotechnol. 2010;2010:934694
references.pmid: 20339476
references.citation: J Gen Virol. 2007 Jun;88(Pt 6):1748-1752
references.pmid: 17485535
references.citation: Nucleic Acids Res. 1994 Nov 11;22(22):4673-80
references.pmid: 7984417
references.citation: Clin Microbiol Rev. 1998 Jul;11(3):480-96
references.pmid: 9665979
references.citation: Antiviral Res. 2012 Dec;96(3):305-14
references.pmid: 23072882
references.citation: Mem Inst Oswaldo Cruz. 2002 Oct;97(7):991-5
references.pmid: 12471426
references.citation: J Virol. 2001 Oct;75(20):9731-40
references.pmid: 11559806
references.citation: Curr Infect Dis Rep. 2010 May;12(3):157-64
references.pmid: 21308524
references.citation: Vaccine. 2008 Feb 6;26(6):817-28
references.pmid: 18191005
references.citation: Virol J. 2005 Aug 24;2:72
references.pmid: 16120221
references.citation: FEBS Lett. 1990 Dec 10;276(1-2):172-4
references.pmid: 1702393
references.citation: J Gen Virol. 2010 Sep;91(Pt 9):2249-53
references.pmid: 20444995